SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
SAN DIEGO, May 31, 2017 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the Jefferies 2017 Global Healthcare Conference to be held in New York City from June 6 - 9, 2017.
The aTyr management team will present an overview of the Company during a presentation at 2:00 p.m. ET on Friday, June 9, 2017. The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com. An audio replay will be available for at least 30 days following the initial presentation webcast.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological pathways. To date, the Company has generated three innovative therapeutic candidate programs based on its knowledge of Physiocrine biology in three different therapeutic areas. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 190 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune imbalance for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
Contact: Mark Johnson Sr. Director, Investor Relations [email protected] 858-223-1163
